BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that it will host a conference call featuring Dr. Hagop Kantarjian, M.D. to provide an update of sapacitabine Phase II clinical plans in patients with elderly AML, review Phase I sapacitabine data reported at the meeting of the American Society of Hematology (ASH) on December 8, and comment on the current therapeutic landscape in acute myeloid leukemia (AML). The call will occur on Wednesday, December 19, 2007 at 9:30 AM Eastern Time.
